Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
We’re catching up on plenty of ASCO news from over the weekend, including detailed daraxonrasib results in pancreatic cancer, and a Chinese lung cancer therapy that continues to outperform expectations.
Also, a decades-old peptide beloved by biohackers has become a lightning rod in a battle over FDA regulation of these substances.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.